Key Stats for HIMS Stock:
- Today’s Price Change: -8%
- Current Share Price: $39
- 52-Week High: $73
- Analysts’ Price Target: $43
What Happened?
Hims & Hers Health (HIMS) stock is down over about 8% today, even though the telehealth company beat consensus estimates in Q1 of 2025.
The company posted adjusted earnings per share of $0.28, which was well above the $0.23 consensus estimate. At the same time, revenue soared to $586 million, easily surpassing the expected $539 million and representing a 111% year-over-year increase from the $278.2 million reported in the same period last year.
Net income reached $49.5 million (20 cents per share), up from $11.1 million (5 cents per share) a year earlier, while EBITDA climbed to $91.1 million, significantly higher than the $61.8 million estimates and the $32.4 million reported in the year-ago quarter.
However, the company’s forward guidance disappointed investors. For the second quarter, Hims & Hers expects revenue between $530 million and $550 million, falling short of the $564.6 million analyst consensus.
Its adjusted EBITDA guidance of $65-75 million for Q2 was roughly in line with analyst expectations of $70.4 million.
See Hims & Hers’ full Q1 earnings transcript & earnings results (It’s free) >>>
What the Market Is Telling Us
Despite impressive first-quarter results, the selloff in HIMS stock suggests investors were focused more on the company’s future outlook than its recent performance.
The lower-than-expected revenue guidance may have raised concerns about a potential slowdown in growth after an exceptional first quarter.
This reaction highlights the high expectations already baked into the stock price. The stock has been volatile in recent months and has already experienced several double-digit price swings.
Notably, HIMS stock surged 20% on April 29th following Novo Nordisk’s announcement that it would offer its weight loss drug Wegovy through telehealth providers such as Hims & Hers.
While this partnership represents a significant opportunity, investors may be reassessing the timeline and impact of such collaborations on the near-term growth trajectory.
Hims & Hers also announced that Nader Kabbani, a 20-year Amazon veteran who oversaw Amazon Pharmacy and the PillPack acquisition, will join as Chief Operations Officer. This suggests that HIMS has a continued focus on operational excellence and scaling the business.
CEO Andrew Dudum’s statement that “more collaborations are coming” and that HIMS expects “wider collaboration across the industry” indicates a strategic push to expand its ecosystem through partnerships with pharmaceutical companies, diagnostic testing providers, and healthcare professionals.
Find the best stocks to buy today that are even better than HIMS. (It’s free) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover.
- Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
